An urgent recall has gone out for a popular medical device used by millions of Americans with diabetes. The US Food and Drug Administration (FDA) has revealed that over two million blood glucose ...
At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...
SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM), a $26.12 billion medical device company with 11.34% revenue growth over the last twelve months, announced the FDA clearance of its Dexcom G7 15 Day Continuous ...
Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Designed to provide real-time glucose readings for an ...
This new technology utilizes data from the Dexcom G7 15 Day sensor to provide personalized insulin recommendations. Alongside this development, DexCom released its third-quarter earnings, reporting a ...
Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback